This Top Artificial Intelligence (AI) Stock Could Have More Upside in 2026

Nvidia shares have risen about 47% over the past year as the ongoing AI spending cycle accelerates, supported by large-scale capex such as Alphabet's announced minimum $175 billion for AI infrastructure. Nvidia is expanding beyond chips into systems and solutions—partnering with Thermo Fisher to deploy DGX Spark-powered AI lab computing for life sciences R&D (an industry that spends roughly $300 billion annually)—and is trading at about 24x this year’s consensus earnings with analysts forecasting a 57% earnings increase this year. The article positions Nvidia as differentiated from custom chip designers like Broadcom and highlights the company’s growing enterprise foothold, presenting the recent pullback as a potential buying opportunity.

Analysis

Market structure: Nvidia (NVDA) is the primary beneficiary as AI capex (e.g., GOOGL’s $175bn) increases demand for GPUs and integrated systems; adjacent beneficiaries include Thermo Fisher (TMO) from lab automation and hyperscaler cloud providers. Incumbent custom-chip designers (Broadcom/AVGO) face pricing pressure as Nvidia pivots from silicon to high-margin systems, shifting share toward vertically integrated solutions and increasing switching costs for enterprise AI buyers.

Risk assessment: Key tail risks are export controls/antitrust actions within 3–12 months, a TSMC capacity shock that raises lead times by >25%, or a demand pullback from hyperscalers that trims FY+1 revenue growth by >20%. Short-term (days–weeks) volatility will be driven by earnings/capex disclosures; medium (3–12 months) by product launches and supply constraints; long-term (1–3 years) by enterprise adoption of agentic AI in $300bn life-sciences R&D budgets.

Trade implications: Favor concentrated NVDA exposure with defined-risk derivatives rather than naked stock: use call spreads for directional upside and put/put-spreads for event hedges; express secondaries via TMO long (life-sciences systems) and a relative short on AVGO (custom chips). Position sizing should be tactical (1–3% portfolio per idea) with stop-losses tied to relative-performance thresholds (10–15%).

Contrarian angles: Consensus underestimates execution/regulatory friction — NVDA’s systems push increases service+software dependency that could compress gross margins if software monetization lags. The market may be underpricing Broadcom’s ability to win custom ASIC business at hyperscalers; consider that a >20% sell-off in NVDA on regulatory headlines would be an asymmetric buying opportunity.

Key Decisions for Investors

• Establish a tactical 2% long position in NVDA on a pullback of 8–12% from current levels or immediately via a 3-month call spread: buy 10% OTM calls and sell 25% OTM calls, allocate 1% notional to the spread and 1% to stock (if comfortable with volatility).
• Initiate a pair trade: long NVDA (1.5% portfolio) vs short AVGO (1.0% portfolio) equal-dollar, target relative outperformance of 10–20% over 3–9 months; cut the pair if NVDA underperforms AVGO by >15% or after 3 months without relative movement.
• Buy TMO as a 1.5% core hold to play life-sciences AI adoption; scale in on pullbacks >12% and target +20% upside over 12–24 months following productization of the DGX Spark integration.
• Purchase a 6-month protective hedge for NVDA sized to 0.5% portfolio: buy a 10% OTM put and sell a 25% OTM put (put spread) to cap drawdown risk from regulatory/export shock; if no adverse regulatory moves in the next 90 days, reduce hedge to 0.25%.